33 research outputs found
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
Large subretinal hemorrhage after intravitreal bevacizumab (Avastin®) for age-related macular degeneration
Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy
Novel heavy dyes for retinal membrane staining during macular surgery: multicentre clinical assessment
Purpose: To evaluate the feasibility of two novel ‘heavy’ dye solutions for staining the internal limiting membrane (ILM) and epiretinal membranes (ERMs), without the need for a prior fluid-air exchange, during macular surgery.
Methods: In this prospective nonrandomized multicenter cohort study, the high molecular weight dyes ILM-Blue™ [0.025% brilliant blue G, 4% polyethylene glycol (PEG)] and MembraneBlue-Dual™ (0.15% trypan blue, 0.025% brilliant blue G, 4% PEG) were randomly used in vitrectomy surgeries for macular disease in 127 eyes of 127 patients. Dye enhanced membrane visualization of the ILM and ERMs, ‘ease of membrane peeling’, visually detectable perioperative retinal damage, postoperative best-corrected visual acuity (BCVA), dye remnants and other unexpected clinical events were documented by 21 surgeons.
Results: All surgeries were uneventful, and a clear bluish staining, facilitating the identification, delineation and removal of the ILM and ERMs, was reported in all but five cases. None of the surgeries required a fluid-air exchange to assist the dye application. BCVA at 1 month after surgery improved in 83% of the eyes in the MembraneBlue-Dual™ group and in 88% in the ILM-Blue™ group. No dye remnants were detected by ophthalmoscopy, and no retinal adverse effects related to the surgery or use of the dyes were observed.
Conclusion: The ‘heavy’ dye solutions ILM-Blue™ and MembraneBlue-Dual™ can be injected into a fluid-filled vitreous cavity and may facilitate staining and removal of the ILM and/or ERMs in macular surgery without an additional fluid-air exchange
Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature
One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection
Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions
Purpose The purpose of this study is to conduct a comparative
analysis of the suspected adverse drug reactions (ADRs)
associated with intravitreal bevacizumab, ranibizumab and
pegaptanib in the WHO database in order to have a real-life
information on these drugs, which now is only based on data
coming from clinical trials.
Methods ADR reports for intravitreal use of bevacizumab,
ranibizumab and pegaptanib from January 2002 to
December 2012 were selected from the WHO-VigiBase.
Reporting odds ratio (ROR) with confidence interval of
95 % and p value was calculated. The analysis was performed
for drug-reaction pairs. The Medical Dictionary for
Regulatory Activities (MedDRA) terminology for ADRs
was used.
Results The analysis was performed on 3180 reports corresponding
to 7753 drug-reaction pairs. Significant RORs for
endophthalmitis and uveitis (1.90, 95 % confidence interval
(CI) 1.48–2.43, and 10.62, 6.62–17.05, respectively) were
retrieved for bevacizumab, and cerebrovascular accident and
myocardial infarction produced significant ROR (1.54, 1.14–
2.10 and 1.73, 1.18–2.53, respectively) for ranibizumab.
Pegaptanib was significantly associated with visual
impairment (1.98, 1.12–3.5, p=0.02), nausea (3.29, 1.57–
6.86, p<0.001), vomiting (2.91, 1.2–7.07, p=0.01) and drug
hypersensitivity (8.75, 3.1–24.66, p<0.001).
Conclusions Our data showed an elevated disproportionality
for cardiovascular ADRs in patients treated with ranibizumab
and for infective ocular reactions in those treated with
bevacizumab. No relevant safety issues were identified for
pegaptanib. These findings suggest bevacizumab as a suitable
choice for AMD therapy due to its effectiveness similar to that
of ranibizumab, its favourable safety profile and for its lower
cost